Biopharmaceutics & Drug disPosition

Papers
(The TQCC of Biopharmaceutics & Drug disPosition is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
39
In situ evaluation of the impact of metformin or verapamil coadministration with vildagliptin on its regional absorption from the rabbit’s intestine35
Decreased plasma acetaminophen glucuronide/acetaminophen concentration ratio warns the onset of acetaminophen‐induced liver injury27
Aging and brain free cholesterol concentration on amyloid‐β peptide accumulation in guinea pigs21
Evaluation of bottom‐up modeling of the blood–brain barrier to improve brain penetration prediction via physiologically based pharmacokinetic modeling19
Issue Information18
14
Evaluating gender effect in the generic bioequivalence studies by physiologically based pharmacokinetic modeling – A case study of dextromethorphan modified release tablets13
Self‐micellizing solid dispersion of tacrolimus: Physicochemical and pharmacokinetic characterization13
Issue Information11
Issue Information10
Issue Information10
Evidence for cytochrome P450 3A4‐mediated metabolic activation of SCO‐26710
Attenuation of phenobarbital‐induced cytochrome P450 expression in carbon tetrachloride‐induced hepatitis in mice models10
Issue Information10
Utility of cystatin C and serum creatinine‐based glomerular filtration rate equations in predicting vancomycin clearance: A population pharmacokinetics analysis in elderly Chinese patients9
Estimation of fraction of drug metabolism by a single UDP‐glucuronosyl transferase enzyme using relative expression factor8
Ampicillin Is a Substrate of Organic Anion Transporters 38
Metabolism and pharmacokinetic study of deuterated osimertinib8
Novel Enteric Microsphere of Beclomethasone Dipropionate With Colon Delivery and Enhancement of Anti‐Inflammatory Effects8
Issue Information8
Irinotecan‐induced gastrointestinal damage alters the expression of peptide transporter 1 and absorption of cephalexin in rats7
Enhanced Vatiquinone Bioavailability With Fatty Meals and Optimal Dosing Schedule7
Predicting transporter mediated drug–drug interactions via static and dynamic physiologically based pharmacokinetic modeling: A comprehensive insight on where we are now and the way forward6
Inhibition of canalicular and sinusoidal taurocholate efflux by cholestatic drugs in human hepatoma HepaRG cells6
The Role of Nasal Drug Delivery in Migraine Management and Brain‐Targeted Therapy: Insights From Taiwan6
Intestinal absorption pathways of lisinopril: Mechanistic investigations6
Species Differences in Carboxylesterases Among Humans, Cynomolgus Monkeys, and Mice in the Hydrolysis of Atorvastatin Derivatives6
Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study6
6
Pharmacokinetic control of orally dosed cyclosporine A with mucosal drug delivery system6
Integration of artificial neural network and physiologically based biopharmaceutic models in the development of sustained‐release formulations5
Pharmacokinetic Studies of a Novel c‐Met Targeting PROTAC Drug Candidate Using UPLC‐MS/MS Quantification Methods5
Issue Information5
Identification and characterization of an endogenous biomarker of the renal vectorial transport (OCT2‐MATE1)4
Involvement of SLC16A1/MCT1 and SLC16A3/MCT4 in l‐lactate transport in the hepatocellular carcinoma cell line4
Issue Information4
Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds4
Prediction of basic drug exposure in milk using a lactation model algorithm integrated within a physiologically based pharmacokinetic model4
4
Comparative Study on Cannabidiol‐Loaded Solubilizing Systems for Improvement of Oral Bioavailability: Liposome and Cyclodextrin‐Based Formulations4
Contribution of Organic Anion Transporter 3 in Delayed Elimination of Methotrexate by Concomitant Administration of Febuxostat4
0.060557842254639